Real-World Evidence on Statin Use for Traumatic Brain Injury Associated Degenerative Neurological Disorders.

Area of Science:

• Neuroscience
• Pharmacology
• Epidemiology

Background:

• Traumatic brain injury (TBI) is a significant risk factor for developing neurodegenerative disorders.
• Statins are being investigated for potential neuroprotective effects, including mitigating neuroinflammation and lipid dysregulation post-TBI.

Purpose of the Study:

• To evaluate the association between statin use and the risk of developing degenerative neurological disorders after a TBI.
• To analyze real-world data on statin use and post-TBI neurological outcomes.

Main Methods:

• A retrospective cohort study was conducted using the TriNetX global research network.
• Propensity score matching (1:1) was employed to balance covariates between statin-treated and untreated groups.
• Cox proportional hazards models assessed risks for dementia, stroke, depression, and Parkinson's disease over a 5-year follow-up period.

Main Results:

• The study included 21,427 patients in each matched group (statin-treated vs. untreated).
• Statin users exhibited significantly higher risks for vascular dementia (HR 2.47), non-vascular dementia (HR 1.45), stroke (HR 1.80), depression (HR 1.91), and Parkinson's disease (HR 1.63).
• Elevated risks were consistent across subgroup analyses by sex and age.

Conclusions:

• Current real-world evidence does not support the use of statins for neuroprotection following TBI.
• Alternative therapeutic strategies targeting TBI-associated neurodegenerative mechanisms are crucial.
• Further research is needed to identify effective neuroprotective agents for TBI patients.